Products Crizotinib has been approved in many countries since 2012 in capsule form (Xalkori). Structure and properties Crizotinib (C21H22Cl2FN5O, Mr = 450.3 g/mol) is an aminopyridine. It exists as a white to yellowish powder that is soluble in acidic solution to 10 mg/mL. Effects Crizotinib (ATC L01XE16) has antitumor and antiproliferative properties. The effects are … Crizotinib
Products Alectinib was approved in capsule form in Japan in 2014, in the United States in 2015, and in many countries in 2017 (Alecensa). Structure and properties Alectinib (C30H34N4O2, Mr = 482.6 g/mol) is present in the drug product as alectinib hydrochloride, a white to yellow-white powder. It has an active metabolite (M4). Effects Alectinib … Alectinib
Products Ceritinib is commercially available in capsule form (Zykadia). It was approved in the United States in 2014 and in the EU and many countries in 2015. In 2020, film-coated tablets were registered. Structure and properties Ceritinib (C28H36N5O3ClS, Mr = 558.14 g/mol) exists as a white to slightly yellow or slightly brown powder. Effects Ceritinib … Ceritinib
